(Q37481292)

20 August 2017

1 reference

title

Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection (English)

1 reference

20 August 2017

1 reference

1 reference

Pierre L Beaulieu

1

1 reference

PubMed ID

19441916

20 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

1 reference

20 August 2017

19

1 reference

20 August 2017

2

1 reference

20 August 2017

145-164

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Unravelling hepatitis C virus replication from genome to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Prospects for a vaccine against the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Hepatitis C virus entry into host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Cyclophilin inhibitors in hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Early steps of the hepatitis C virus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Nucleoside analog inhibitors of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Allosteric inhibitors of hepatitis C polymerase: discovery of potent and orally bioavailable carbon-linked dihydropyrones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

The culture of designing hepato-biliary randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802672598

10.1517/13543770802672598

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19441916